GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-06-27| Trials & Approvals

Clinical Hold Announced for Arcellx’s IMMagine-1 Phase 2 Clinical Program

by GeneOnline
Share To

The biotechnology company Arcellx has announced that the phase 2 clinical program for their multiple myeloma cell therapy candidate iMMagine-1 has been placed on hold following a notification from the U.S. Food and Drug Administration (FDA). 

Related Article: Kite Buys Tmunity To Chase Next-Generation CAR T-Cell Therapies

Hold on IMMagine-1 Phase 2 Clinical Program 

On June 19, Arcellx issued a press release stating that a clinical hold had been placed on iMMagine-1, a drug for the treatment of refractory myeloma (rrMM). The FDA’s notification was received on June 16 in the wake of a patient’s death. Despite this, they have been provided with clearance to continue the dosing of patients who have undergone lymphodepletion. Arcellx believes a contributing factor to the event is the limitations of bridging therapy. Bridging therapy is the treatment between the collection of T cells and lymphodepletion. 

The company has affirmed that their priority remains patients’ safety and well-being. Rami Elghandour,  Arcellx’s Chairman and Chief Executive Officer, commented, “In coordination with our investigators, data safety monitoring board (DSMB), and our partners at Kite Pharma, we are working with FDA to address the clinical hold. The expansion of bridging therapy regimens is consistent with what’s currently available in clinical practice and is in the best interest of patients. Additionally, we continue to evaluate other potential improvements to the study. We remain confident that CART-ddBCMA is a potential best-in-class therapy for the treatment of patients with rrMM based on the clinical profile observed in the patients dosed to date across our studies. The drug product release characteristics from iMMagine-1 are consistent with those from our Phase 1 study. The manufacturing success rate remains 100% while ramping Lonza, our cell therapy manufacturer, to full scale. Fourteen clinical sites have been opened and study enrollment is tracking to our expectations. We look forward to resolving this matter expeditiously and to continue to advance our therapy to the benefit of patients suffering from rrMM.” 

CAR-T cell Treatment in Multiple Myeloma

Multiple myeloma is a hematological cancer that generally affects the skull, pelvis, ribs, and spine. This type of bone marrow cancer affects blood cell production and causes damage to the patient’s bones.  It is a relatively uncommon cancer that accounts for about 10% of all  hematological cancers and around 2% of all cancer deaths in the US. Although the cause of multiple myeloma is yet unknown, it can be linked to the non-malignant condition multiple monoclonal gammopathy of undetermined significance (MGUS). MGUS can often develop into multiple myeloma. This happens because in both conditions there is an abnormal production of M proteins by plasma cells.

IMMagine-1 is a CAR T-cell therapy drug candidate for the treatment of multiple myeloma. CAR T-cell therapy is a form of immunotherapy that uses genetically modified T cells to target cancer cells. These therapies fight cancer by using our body’s own immune system and are customized to each individual. Typically, a patient’s T cells are collected and engineered to produce chimeric antigen receptors (CARs). CARs are able to bind to antigens or proteins on cancer cells that normal T cells can’t recognize as atypical. In the case of Arcellx’s iMMagine-1, the T cells have been engineered to kill cells that express an antigen for multiple myeloma.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Getting a Full View: 5 Breakthrough Biotech Stocks to Watch in 2025
2025-01-06
R&D
Senolytic CAR T Cells: A Revolutionary Approach to Combat Age-Related Metabolic Dysfunction and Senescence-Associated Diseases
2024-01-29
Global Biotech Elites Gather to Explore Trends and Prospects of Cell and Gene Therapies
2023-08-09
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top